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Abstract
Background Obesity-related chronic pain can increase the risk of narcotic abuse in bariatric surgery patients. However,
assessment of overdose risk has not been evaluated to date.
Methods A NARxCHECK® overdose score (“Narx score”) was obtained preoperatively on all patients undergoing bariatric
surgery (n = 306) between 2018 and 2020 at a single-center academic bariatric surgery program. The 3-digit score ranges from
000 to 999 and is based on patient risk factors found within the Prescription Drug Monitoring Program. A Narx score ≥ 200
indicates tenfold increased risk of narcotic overdose. Patient characteristics, comorbidities, and emergency room (ER) visits
were compared between patients in the upper (≥ 200) and lower (000) terciles of Narx scores. Morphine milligram equivalent
(MME) prescribed at discharge and refills was also evaluated.
Results Patients in the upper tercile represented 32% (n = 99) of the study population, and compared to the lower tercile
(n = 101, 33%), were more likely to have depression (63.6% vs 38.6%, p = 0.0004), anxiety (47.5% vs 30.7%, p = 0.0150),
and bipolar disorder (6.1% vs 0.0%, p = 0.0120). Median MME prescribed at discharge was the same between both groups
(75); however, high-risk patients were more likely to be prescribed more than 10 tablets of a secondary opioid (83.3% vs
0.0%, p = 0.0111), which was prescribed by another provider in 67% of cases. ER visits among patients who did not have a
complication or require a readmission was also higher among high-risk patients (7.8% vs 0.0%, p = 0.0043). There were no
deaths or incidents of mental health-related ER visits in either group.
Conclusion Patients with a Narx score ≥ 200 were more likely to have mental health disorders and have potentially avoidable
ER visits in the setting of standardized opioid prescribing practices. Narx scores can help reduce ER visits by identifying
at-risk patients who may benefit from additional clinic or telehealth follow-up.
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Obesity is associated with increased risk of prescription opioid use as a result of weight-related chronic pain conditions
[1, 2]. In fact, a Body Mass Index (BMI) of 40–49.9 kg/m2 is
associated with 158% increased odds of incident long-term
prescription opioid use, with joint pain, back pain, injury,
and muscle and nerve pain among the most common reasons
for opioid use [3]. In addition, the incidence of new persistent opioid use is as high as 6.3% among patients undergoing
primary bariatric surgery [4]. Although bariatric surgery is
the most effective and durable treatment for obesity, candidates may be at higher risk for opioid misuse postoperatively, especially in the setting of chronic prior use. To date,
there are no data on the overdose risk among patients undergoing bariatric surgery.
An objective measure to predict unintentional overdose
from narcotics has been developed using data from the Prescription Drug Monitoring Program (PDMP), which generates three-digit NARxCHECK® scores ranging from 000
to 999 for Narcotics, Sedatives, Stimulants, and Overdose.
An overdose score (“Narx score”) of 000 indicates no prior
narcotic, sedative, or stimulant prescriptions, while a Narx
score of 200 increases the odds ratio of unintentional overdose death by 10 [5]. The Michigan Automated Prescription System (MAPS) is the state’s PDMP that provides prescribers and dispensers with real-time prescription data and
analytics of controlled substances and schedule 2–5 drugs
that have been dispensed, and the report provides the Narx
score, which is also used to guide when naloxone should
be prescribed [6]. The MAPS report must be reviewed by
providers before prescribing any opioids [7].
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In this context, we hypothesized that patients with higher
Narx scores will have higher rates of postoperative ER visits
and narcotic refills. As such, we utilized a statewide bariatric-specific clinical registry to identify patients undergoing
bariatric surgery at a single-center academic institution. We
evaluated the relationship between preoperative Narx scores
and patient characteristics, opioid prescribing patterns, and
postoperative emergency room (ER) visits among patients
with high and low scores.

Materials and methods
Study design
This study was designed to characterize the distribution of
Narx scores among patients undergoing bariatric surgery
and compare prescribing practices and ER visits between
patients with high and low scores. A Narx score was
obtained during the preoperative assessment on all patients
undergoing bariatric surgery (n = 306) between 2018 and
2020 at a single-center academic bariatric surgery program.
Patient characteristics, comorbidities, length of stay, morphine milligram equivalent (MME) prescribed at discharge,
and number of refills and ER visits within 30 days of surgery
were obtained using data from the Michigan Bariatric Surgery Collaborative (MBSC), a statewide bariatric-specific
clinical data registry used for clinical quality improvement
[8]. Patients were stratified into terciles according to their

Surgical Endoscopy

Narx score: lower tercile = 000, middle tercile = 001 to 199,
and upper tercile = 200 to 999.
The primary outcome variable was number of refills
within 30 days of surgery. Secondary outcome measures
included both ER visits and preventable ER visits within
30 days of surgery, MME prescribed at discharge, and length
of stay. Preventable ER visits were defined as ER visits
among patients who did not have a complication or require
readmission.

and χ 2 tests for categorical characteristics. In order to
compare baseline Narx scores, we used non-parametric
Mann–Whitney U tests to compare medians between the
upper and lower terciles.
Risk and reliability-adjusted comparisons of 30-day
prescribing patterns and complication rates were compared
between the upper and lower terciles using multivariate
logistic regression for categorical outcomes and multivariate linear regression for continuous outcomes.

Data collected
NARxCHECK® analyzes data from PDMPs using a patented algorithm to generate a 3-digit Narx score [5]. The
Narx score is a weighted combination of many variables:
drug equivalents, number of providers, potentiating drugs,
number of pharmacies, and number of overlapping prescription days. In any given population, Narx scores are distributed such that about 75% of scores are below 200, about 5%
are above 500, and about 1% of scores are above 650. Additionally, the number of active prescriptions that a patient
will have, assuming medications are taken as directed, is
represented by the last digit of the Narx score. Under state
law, Narx scores must be reviewed by providers before prescribing any opioids.
Our standard pain management protocol was for 10 pills
of 5 mg oxycodone, unless there was an intolerance or
allergy. Additional practices to help prevent overprescribing
opioids and decrease the rate of new persistent use included
eliminating patient controlled analgesia, administering transversus abdominis plane blocks in the OR, using IV acetaminophen for gastric bypass and IV ketorolac for sleeve gastrectomy patients, and providing abdominal binders and hot
and ice packs for multimodal pain therapy.
Patient characteristics collected include age, preoperative
BMI, sex, race, education, marital status, employment, disability, and insurance type. Patient comorbidities included
diabetes, hypertension, hyperlipidemia, sleep apnea, mobility disorder, psychologic disorder, depression, anxiety,
bipolar disorder, and eating disorder. All patients underwent
either laparoscopic gastric bypass or laparoscopic sleeve
gastrectomy.

Statistical analysis
Patients were divided into three tercile groups based on their
overall Narx scores with patients with scores of 000 as the
lower tercile, scores from 1 to 199 as the middle tercile, and
scores 200 to 999 as the upper tercile.
Comparisons of baseline patient characteristics were
performed between the upper and lower terciles using
independent samples t tests for continuous variables

Results
A total of 306 patients were included in the study. Overall
mean age was 45.1 years, 20.9% were male, 78.0% were
White, and the mean preoperative BMI was 48.0 kg/m2.
Figure 1 shows the distribution of Narx scores in this study
cohort. For the entire cohort, the preoperative median
Narx score was 120. Patients in the upper tercile had a
baseline median Narx score of 280 and patients in the middle tercile had a median Narx score of 120.
Table 1 compares patient characteristics, preoperative
comorbid conditions, and procedure type between the
upper and lower terciles. Patients had similar age (46.3
vs. 43.9 years, p = 0.1117) and preoperative BMI (48.3
vs. 47.7 kg/m2, p = 0.5771). Proportions of patients with
diabetes, hypertension, sleep apnea, and mobility disorder
were also similar between the upper and lower terciles.
When compared to patients in the lowest tercile, patients
in the upper tercile were more likely to have psychiatric disorders (70.7% vs. 47.5%, p = 0.0009), specifically,
depression (63.6% vs 38.6%, p = 0.0004), anxiety (47.5%
vs. 30.7%, p = 0.0150), and bipolar disorder (6.1% vs.
0.0%, p = 0.0120). Similar proportions of patients in the
upper and lower terciles underwent gastric bypass and
sleeve gastrectomy.
Table 2 shows that the median MME prescribed at discharge was the same between patients in the upper and
lower terciles (75 MME). However, patients in the upper
tercile were more likely to be prescribed more than 10
tablets of a secondary opioid (83.3% vs. 0.0%, p = 0.0111)
after hospital discharge. In addition, in 67% of the cases,
the secondary opioid prescription was prescribed by a provider who was not with the bariatric surgery program. ER
visits among patients who did not have a complication or
require a readmission were also higher among patients in
the upper tercile (7.8% vs. 0.0%, p = 0.0043). Of these preventable ER visits, all patients presented with symptoms
(i.e., postoperative pain or nausea) without any additional
diagnoses. There were no reported deaths, overdoses, or
incidences of mental health-related visits to the ER in
either group.
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Fig. 1  Distribution of Narx
scores for patients undergoing
bariatric surgery between 2018
and 2020 at a single-center
academic center

Discussion
This is the first study to report Narx scores among patients
undergoing bariatric surgery, thus shedding new light on
the burden of obesity-related pain as well as postoperative
opioid prescribing practices at a single-center academic
institution. We found that patients in the upper tercile for
Narx score (32% of patients) had a score of 200 or greater,
indicating a tenfold increased risk of unintentional overdose
death as compared to opioid-naïve patients [5]. Patients in
the upper tercile for Narx score were also more likely to
have depression, anxiety, bipolar disorder, and preventable
ER visits when compared to patients in the bottom tercile.
Although there was no difference in MME prescribed at
discharge among the groups, we found that patients with
the highest Narx scores were more likely to be prescribed
more opioids after their hospital discharge and that refills
were more likely prescribed by another provider. Our study
demonstrates that obtaining Narx scores preoperatively may
help tailor opioid prescribing practices and also identify atrisk patients who may benefit from additional strategies to
further decrease opioid use and preventable ER visits.
These results are consistent with the literature suggesting
that obesity is associated with prescription opioid use due
to weight-related chronic pain conditions, particularly joint
pain, back pain, injury, and muscle and nerve pain [1–3].
Our findings contribute to the literature by investigating the
association of preoperative Narx scores with characteristics, complications, and outcomes of patients undergoing
bariatric surgery. Narx scores have been evaluated among
patients undergoing elective spine surgery, and no association was found between Narx scores and rates of adverse
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events, readmission, reoperation, or mortality [9]. In patients
undergoing primary total hip, higher Narx scores were associated with higher odds of 90-day all-cause readmission,
procedure-related admission, longer length of stay, and nonhome discharge [10]. In bariatric surgery, studies have examined the effects of opioid use on patient outcomes. Shockcor et al. showed similar weight loss, 30-day readmission,
reoperation, venothrombotic event rate, bleeding rate, and
infection rate between chronic prescription opioid users and
opioid-naïve controls [11]. Raebel et al. demonstrated that
8% of patients in their study population were chronic opioid
users, with 77% of these patients continuing opioid use one
year after surgery. Furthermore, they showed that MMEs
for these patients increased postoperatively, but no change
in MME was found in the subgroup of patients with depression or chronic pain [12]. These studies in bariatric surgery
provide insight into the impact of preoperative opioid use
on patient outcomes but only divides patients into binary
categories (i.e., chronic vs. not chronic opioid users) rather
than further stratifying opioid users based on an objective
risk score.
In our study of bariatric surgery patients, only 67.7% of
patients had a Narx score less than 200, which is approximately 7% lower than the expected proportion of patients in
this range of Narx scores. According to the NARxCHECK®
algorithm, in any given population, the distribution of scores
are such that about 75% of scores are less than 200, about
5% are above 500, and only 1% are above 650 [5]. In two
studies, 74.9% of patients undergoing primary total hip
arthroplasty and approximately 75% of patients undergoing
elective spine surgery had a Narx score below 200 [9, 10].
The smaller proportion of bariatric surgery patients with a
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Table 1  Comparison of demographics, comorbidities, and procedure type between upper and lower terciles according to Narx score
% or mean (range)

Overall

Lower tercile (Narx
score 000 to 000)

Middle tercile (Narx
score 001 to 199)

Upper tercile (Narx
score 200 to 999)

p-value

n
NARxCHECK® (Median)
Narcotics
Stimulants
Sedatives
Overdose (“Narx score”)
Demographics
Age
Preoperative BMI
% Male
White
Non-white
College
Married/Sig other
Employed
Disabled
Private insurance
Medicare
Medicaid
Comorbidity
Diabetes
NIDDM
IDDM
Hypertension
Hyperlipidemia
Sleep apnea
Mobility disorder
Psychiatric disorder
Depression
Anxiety
Bipolar disorder
Eating disorder
Procedure type
Gastric bypass
Sleeve gastrectomy

306

101 (33%)

106 (35%)

99 (32%)

40.0
0.0
25.0
120.0

0.0
0.0
0.0
0.0

40.0
0.0
30.0
120.0

120.0
0.0
80.0
280.0

45.1 (21.8–75.3)
48.0 (35.5–72.5)
20.9
78.0
22.0
90.8
57.8
73.6
9.6
89.2
8.8
1.6

43.9 (21.8–70.3)
47.7 (35.7–69.2)
27.7
70.7
29.3
95.2
65.1
75.9
6.0
93.1
5.9
1.0

45.2 (22.9–75.3)
48.0 (35.5–68.6)
19.8
80.5
19.5
92.3
54.6
81.0
8.9
91.5
6.6
0.9

46.3 (24.8–72.0)
48.3 (36.0–72.5)
15.2
83.1
16.9
84.4
53.3
63.6
14.3
82.8
14.1
3.0

0.1117
0.5771
0.0305
0.0647
0.0647
0.0233
0.1285
0.0907
0.0818
0.0259
0.0533
0.3028

36.0
67.3
32.7
47.1
39.5
69.3
4.9
63.7
54.3
43.5
2.6
2.3

38.6
69.2
30.8
41.6
30.7
69.3
3.0
47.5
38.6
30.7
0.0
0.0

33.0
62.9
37.1
46.2
41.5
71.7
5.7
72.6
60.4
51.9
1.9
5.7

36.4
69.4
30.6
53.5
46.5
66.7
6.1
70.7
63.6
47.5
6.1
1.0

0.7424
0.9840
0.9840
0.0906
0.0219
0.6890
0.2919
0.0009
0.0004
0.0150
0.0120
0.3113

8.8
91.2

10.9
89.1

9.4
90.6

6.1
93.9

0.2207
0.2207

< 0.0001
0.1271
< 0.0001
< 0.0001

NIDDM non-insulin-dependent diabetes mellitus, IDDM insulin-dependent diabetes mellitus
p-value displayed is for Mann–Whitney-signed rank test due to non-normally distributed data

low Narx score is further evidence that obesity is associated
with elevated odds of prescription opioid use, likely due to
weight-related chronic pain conditions [1, 2].
Overall, only 3.9% of patients in this study required a
secondary opioid prescription, and this proportion was not
significantly different between patients in the upper and
lower terciles (6.2% vs. 3.0%, p = 0.2844). This finding
suggests that for most patients, current opioid prescriptions
at discharge are sufficient to achieve adequate pain control
after surgery. Friedman et al. reported that as recently as

late 2017, opioid prescriptions were still variable and excessive for most patients undergoing bariatric surgery (n = 53
for sleeve gastrectomy, n = 50 for gastric bypass, n = 12 for
laparoscopic adjustable gastric banding) [13]. Furthermore,
Ehlers et al. showed that in their study population of 33
patients undergoing bariatric surgery, 73% had leftover
narcotics, only 36% thought they had been prescribed “too
much” pain medication, and 53% kept leftover opioids rather
than disposing of them [14]. Similarly, in a national survey
among the US adults with recent opioid medication use,
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Table 2  Comparison of opioid prescribing practices and 30-day risk-adjusted outcomes between upper and lower terciles according to Narx
score
% or mean (range)

Overall

Lower tercile (Narx Middle tercile (Narx Upper tercile (Narx
score 000 to 000)
score 001 to 199)
score 200 to 999)

p-value

n
Opioid prescribing practices
% Prescribed with an opioid at discharge
By surgeon
Other provider
Median total MME prescribed at discharge
% secondary opioid prescribed
By surgeon
Other provider
Secondary opioid quantity
< 10
10
> 10
30-day risk-adjusted outcomes
Any complications
Extended length of stay
Readmissions
ER visits
ER visits (without readmission or complications)

306

101

106

99

87.3
99.6
0.4
75 (0–1500)
3.9
58.3
41.7

85.2
98.8
1.2
75 (0–225)
3.0
100.0
0.0

89.6
100.0
0.0
75 (0–562.5)
2.9
66.7
33.3

86.9
100.0
0.0
75 (0–1500)
6.2
33.3
66.7

33.3
8.3
58.3

100.0
0.0
0.0

33.3
0.0
66.7

0.0
16.7
83.3

0.0111

9.3
1.8
3.4
10.1
5.2

8.1
1.4
4.2
7.1
0.0

7.7
1.4
2.9
10.3
8.5

13.2
2.8
3.0
13.3
7.8

0.3547
0.4898
0.8578
0.4917
0.0043

0.7259
0.3159
0.5715
0.2844
0.1667

NIDDM non-insulin-dependent diabetes mellitus, IDDM insulin-dependent diabetes mellitus
p-value displayed is for Mann–Whitney-signed rank test due to non-normally distributed data

Kennedy-Hendricks et al. reported that 61.3% of respondents reported keeping leftover opioid medications for future
use [15]. Any excess opioid medication that is not properly
disposed of still carries a risk for overdose in the patient and
in others, as 20.7% of patients reported ever having shared
opioid medications with another person [15]. Although
Narx scores were predictive of secondary prescriptions from
another provider and preventable ER visits, it remains to be
seen if the score can be used for patient-specific prescribing
practices to further reduce opioid use and excessive opioid
prescriptions among patients undergoing bariatric surgery.
It is important to note that our bariatric surgery program
was actively engaged in a statewide initiative to decrease
opioid prescribing during the study period, which likely
explains why we found no differences in MME prescribed
at discharge among the groups. The University of Michigan
does this through the Michigan Opioid Prescribing Engagement Network (M-OPEN) and is the coordinating center and
participant of the Finding Useful Techniques to Upgrade
Recovery Enhancement (FUTURE) initiative through the
MBSC, which includes using multimodal pain therapy to
reduce opioid use. After this study was conducted, our bariatric surgery program further reduced the standard prescription of opioids to 8 pills of 5 mg oxycodone for patients
with preoperative Narx scores of 000 to 100, especially since
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12.7% of all patients in this study did not require an opioid prescription at discharge. The MBSC is now actively
engaged in studies that evaluate opioid-free bariatric surgery.
Overall, 10.1% of patients presented to the ER within
30 days of surgery. Even though there was no statistically
significant difference in rates of ER visits between patients
in the upper and lower terciles, patients in the upper tercile had higher rates of preventable ER visits (i.e., ER visits that were not due to a complication and did not require
readmission) as compared to the lower tercile. Khouri et al.
found anxiolytic prescription at discharge (odds ratio 5.4
[95% confidence interval 1.6–18.6]) to be an independent
risk factor associated with preventable ED visits [16]. In
this context, the higher prevalence of psychiatric disorders
in patients in the upper tercile may be a contributing factor
for the increased rates of preventable ER visits in this group.
Furthermore, opioids are known to exacerbate nausea, vomiting, and constipation after surgery [17]. The larger amounts
of secondary opioid prescriptions in patients in the upper
terciles may also contribute to ER visits for medication side
effects that were not severe enough to require readmission.
We believe that Narx scores can help providers identify
at-risk patients who may benefit from more rigorous presurgical counseling as well as additional clinic or telehealth
follow-up after surgery. For these patients, studies suggest
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that the best outcomes can be achieved by giving patients
realistic expectations of the anticipated postoperative pain
and managing these expectations via patient education and
specifically written instructions before the surgery [18].
Our typical follow-up after bariatric surgery is at 2 weeks,
2 months, 6 months, and then annually thereafter. For atrisk patients, additional in-person clinic visits or telehealth
appointments within the first month after surgery may help
address unanticipated patient concerns, minimize secondary opioid prescriptions written by providers not part of the
bariatric surgery program, and decrease rates of preventable
ER visits.

Limitations
This study has several limitations. First, this study only
includes patients undergoing bariatric surgery at a singlecenter academic bariatric surgery program between 2018
and 2020, which may limit generalizability. Calculating a
Narx score was not a part of the electronic medical record
functionality until 2018, so data prior to this date could not
be captured. Nevertheless, we did have 100% data capture
rate on all patients, which included follow-up at 30 days.
Second, Narx scores were not blinded from providers during the study period. Blinding was not possible as it is state
law for prescribers to review all patients’ Narx scores before
prescribing narcotics, so we are unable to determine whether
knowledge of higher or lower Narx scores had any impact
on decision-making for treatment of pain. Third, we evaluated opioid prescriptions and additional need through refills
as a proxy for narcotic use, which may result in inaccuracies. Specifically, patients could have had illicit opioid use,
thereby underestimating the actual amount of opioid use
after surgery or alternatively, patients may not have filled
their prescription and not used any opioids at all. Finally, it
should be noted that data obtained for this study occurred
during a period when standardized prescribing practices
were in effect in order to reduce opioid use. These practices
explain why the median MME prescribed at discharge for all
group were similar and also why 12.7% of patients did not
require a prescription for opioids at discharge, even among
patients in the upper tercile of Narx scores.

Conclusion
Bariatric surgery patients with a Narx score of 200 or more
were more likely to have mental health disorders and were
also more likely to have preventable ER visits than opioidnaïve patients. Narx scores can help providers identify atrisk patients who may benefit from additional preoperative
counseling and additional follow-up to reduce unnecessary

ER visits or overprescribing of opioids after bariatric
surgery.
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